Amgen (AMGN) Stock News

Wells Fargo reduced its price target for Amgen from $435.00 to $430.00.

UBS increased its price target for Amgen from $430.00 to $470.00 per share.

RBC Capital increased its price target for Amgen from $400.00 to $430.00 per share.

Amgen's Phase 3 OASIZ 301 trial for dazodalibep in moderate-to-severe Sjögren's disease met its primary endpoint. The 621-patient study showed significant improvement in systemic disease activity by Week 4, sustained through Week 48. No FDA-approved therapies exist. A second Phase 3 study (OASIZ 303) in symptomatic Sjögren's is expected to complete in Q4.